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Regular Article
IMMUNOBIOLOGY
Distinct severity of HLH in both human and murine mutants with complete
loss of cytotoxic effector PRF1, RAB27A, and STX11
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Key Points
• Syntaxin-11–deficient
(Stx11/) murine model faith-
fully reproduced the manifes-
tations of HLH after LCMV
infection.
• HLH severity differed signifi-
cantly with a severity gradient
from perforin (early onset)
Rab27a syntaxin-11 (late on-
set).
Inherited defects of granule-dependent cytotoxicity led to the life-threatening immune
disorder hemophagocytic lymphohistiocytosis (HLH), characterized by uncontrolled
CD8 T-cell and macrophage activation. In a cohort of HLH patients with genetic
abnormalities expected to result in the complete absence of perforin, Rab27a, or
syntaxin-11, we found that disease severity as determined by age at HLH onset differed
significantly, with a severity gradient from perforin (early onset)> Rab27a> syntaxin-11
(late onset). In parallel, we have generated a syntaxin-11–deficient (Stx11/) murine
model that faithfully reproduced the manifestations of HLH after lymphocytic choriomen-
ingitis virus (LCMV) infection. Stx11/ murine lymphocytes exhibited a degranulation
defect that could be rescued by expression of human syntaxin-11 but not expression of a
C-terminal–truncated mutant. Comparison of the characteristics of LCMV infection-
induced HLH in the murine counterparts of the 3 human conditions revealed a similar
gradient in the phenotypic severity of HLH manifestations. Strikingly, the severity of HLH
was not correlated with the LCMV load and not fully with differences in the intensity of
cytotoxic activity. The capacity of antigen presentation differed in vivo between Rab27a- and Syntaxin-11–deficient mutants. Our
data indicate that cytotoxic effectors may have other immune-regulatory roles in addition to their role in controlling viral replication.
(Blood. 2013;121(4):595-603)
Introduction
The relevance of the immune surveillance performed by cytotoxic
T cells (CTLs) is emphasized by immunopathologic disorders that
occur when inherited deficiencies impair the cells’ cytotoxic
activity. These disorders result in an often fatal condition known as
hemophagocytic lymphohistiocytosis (HLH),1 which is character-
ized by a nonremitting fever, hepatosplenomegaly, neurologic
alterations, hypercytokinemia, expansion and accumulation of
activated polyclonal CD8 T cells, organ infiltration by activated
macrophages, and subsequent hemophagocytosis (ie, phagocytosis
of blood cells).2 It is considered that an absence of virus control
leads to sustained, polyclonal CTL activation and subsequently
excessive macrophage activation.1,2
Inherited forms of HLH are caused by mutations in genes for
several proteins, including perforin (PRF1),3 Munc13-4 (UNC13D),4
syntaxin-11 (STX11),5 Munc18-2 (STXBP2),6,7 SAP (SH2D1A),
and XIAP (XIAP).8 HLH may also be associated with hypopigmen-
tation, as in Griscelli syndrome (GS; RAB27A)9 and Chediak-
Higashi syndrome (LYST).10,11 In general, HLH-causing mutations
affect genes involved in the granule-dependent cytotoxic pathway
in CTLs.12 Syntaxin-11 (STX11) is an atypical SNARE that lacks a
carboxy-terminal, hydrophobic, transmembrane domain; instead, it
contains a putative palmitoylation motif at the C-terminus that
might enable membrane interaction.13 STX11 deficiency causes
familial hemophagocytic lymphohistiocytosis type 4 (FHL4).5,14
Murine models of HLH have improved our understanding of the
disease mechanism in HLH. Four murine HLH models are
available: perforin-deficient (Prf1/),15 ashen (Rab27a/),16 jinx
(Unc13d/),17 and souris (Lyst/).18 On lymphocytic choriomen-
ingitis virus (LCMV) infection, all 4 models develop most of the
HLH features observed in patients. By studying these murine
models, we and others have highlighted the pivotal role played by
CD8 T cells and IFN- in the development of HLH, the latter
being a putative therapeutic target.15,19
Here, we describe the generation and characterization of a new
murine model of HLH (the Stx11/ mouse). We show that
Stx11/ mice faithfully recapitulate the key features of human
HLH and represent a suitable model for studying FHL4 in vivo and
the role of Stx11 in vitro. By comparing the severity of HLH in
Stx11/ mice with that observed in Rab27a/ and Prf1/ mice,
we established a clear correlation between the murine mutants and
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the age at HLH onset in their human counterpart. Furthermore, our
findings indicate that cytotoxic effectors may have other immune
regulatory roles in addition to their role in controlling viral
replication.
Methods
Patients
All patients with HLH diagnosis were either previously published or
referred for molecular screening (supplemental Tables 1 and 2, available on
the Blood Web site; see the Supplemental Materials link at the top of the
online article). Patients were diagnosed using classic HLH criteria.2 Written
informed consent for genotyping and data collection was obtained from the
parents. The study was conducted according to the guidelines of the
Declaration of Helsinki. All protocols were approved by the Inserm’s
institutional review board.
Sequence analysis
DNA samples were prepared from peripheral blood mononuclear cells
using standard methods. DNA was used for exon PCR amplification of
PRF1, RAB27A, and STX11 genes and sequenced (primer sequences
available on request).
Mice
Conditional Stx11/ mutant mouse line was established at the Mouse
Clinical Institute–Institut Clinique de la Souris (Illkirch, France). The
targeting vector was constructed as follows. A 3.7-kb fragment correspond-
ing to the 3 homology arm and encompassing exon 2 was amplified by
PCR and subcloned in an MCI proprietary vector, resulting in step 1
plasmid. This MCI vector has a floxed neomycin resistance cassette. A
2.4-kb fragment encompassing the floxed exon 3 was amplified by PCR and
subcloned in step 1 plasmid to generate step 2 plasmid. Finally, a 4-kb
fragment corresponding to the 5 homology arm was subcloned in the step 2
plasmid to generate the final targeting construct. The linearized construct
was electroporated in BD10 (C57BL/6N background) mouse embryonic
stem cells. After selection, targeted clones were identified by PCR using
external primers and further confirmed by Southern blot with 5 and 3
external probes. Positive embryonic stem clones were selected and injected
into Balb/CN blastocysts, and male chimaeras derived gave germline
transmission. To inactivate the syntaxin-11 gene ubiquitously, Stx11 fl/fl
mice were crossed with C57BL/6 mice carrying the Cre recombinase under
the control of the CMV promoter. The transgene was eliminated by genetic
segregation. The total excision of neo and exon 3 of Stx11 was confirmed
by analysis of the PCR products. C57BL/6J WT, C57BL/6J-Prf1tm1Sdz/J,
and C57BL/6J-Rab27aash/J have been described previously.19 All mice,
except Rab27a-deficient mice, were generated on C57BL/6 background.
Rab27a-deficient mice were backcrossed to the C57BL/6 background in
 15 generations. Mice were maintained in pathogen-free conditions
and handled accordingly to national and institutional guidelines.
Induction of HLH by LCMV infection
The WE strain of LCMV was kindly provided by Professors Maries van de
Broek and Rolf Zinkernagel (University of Zu¨rich, Zu¨rich, Switzerland).
Mice 6-10 weeks of age received an intraperitoneal injection of 200 pfu of
viral particles. Blood counts were checked for several days after infection
using an automated cell counter (the MS 9-5 V, Melet Schloesing
Laboratories). Serum levels of lactate dehydrogenase and aspartate amino-
transferase were determined using the VetTest Chemistry Analyzer (IDEXX
Laboratories). The serum IFN- concentration was determined using an
ELISA kit (eBioscience). The serum levels of other cytokines and
chemokine were quantified using multiplex assays (Invitrogen). To quantify
CXCL10 production in infected tissues, total RNA was purified using an
RNeasy Mini kit (QIAGEN) and cDNA was prepared using the QuantiTect
Reverse Transcription kit (QIAGEN). Real-time PCR was performed with a
TaqMan Probe Mix (Applied Biosystems) using predesigned primer/probe
sets for mouse -actin (Mm 00607939_s1) and CXCL10 (Mm
00445235_m1; Applied Biosystems).
The quantification of the LCMV load in organs was performed by
quantitative PCR, as described previously.19 Briefly, cDNA was isolated
from tissue samples and analyzed with primers for LCMV (forward:
5-TCTCATCCCAACCATTTGCA-3 and reverse: 5-GGGAAATTTGAC
AGCACAACAA-3) and -actin (forward: 5-CCAGCAGATGTGGAT
CAGCA-3 and reverse: 5-CTTGCGGTGCACGATGG-3) using SYBR
Green PCR Master Mix (Applied Biosystems).
In vitro CD8 T-cell activation and degranulation and
cytotoxicity assays
Spleen CD8 T cells were purified from the spleen and activated in vitro
with a T-cell activation/expansion kit (Miltenyi) in the presence of 50 U/mL
of recombinant IL-2. After 5 days, T-cell degranulation was assayed by
activating 4  105 cells with different concentrations of anti-CD3e (clone
500A2, eBioscience), in the presence of FITC-coupled anti-CD107a (clone
1D4B, eBioscience) and anti-CD107b (ABL-93, eBioscience) antibodies.
Degranulation capacity was assayed in CD8 T cells supplemented or not
with 1000 U/mL of recombinant IL-2 and compared with nonactivated cells
and the corresponding isotype control. CD8 T-cell cytotoxicity was
quantified using the CytoTox96 Non-Radioactive Cytotoxicity Assay
(Promega). Anti-CD3–loaded P815 cells were used as targets.
CD8 T-cell transfection
Using a nucleofection kit (AMAXA Biosystems) according to the manufac-
turer’s instructions, 5  106 in vitro-activated CD8 T cells were cotrans-
fected at day 4 with 3 g of cDNA coding for CFP plus WT human STX11
or the truncated Y255X mutant. Sixteen hours later, cells were harvested
and the degranulation capacity was assayed as described in the previous
paragraph.
In vivo T-cell proliferation. To quantify T-cell proliferation, CFSE-
labeled P14 CD45.1 CD8 T cells were transferred into control, Stx11/,
Rab27a/, and Prf1/ CD45.2 mice previously infected with 200 pfu of
LCMV 7 days previously. Three days later, CFSE dilution was assessed by
FACS analysis (gated on CD8 CD45.1 cells).
In vitro NK cell culture and degranulation assay. NK cells were
purified from the spleen (Miltenyi, NK cell isolation kit) and cultured in
vitro in the presence of 30 ng/mL of recombinant IL-15. After 6-8 days, NK
cell degranulation was assayed by activating 5  105 cells with target
YAC-1 cells, in the presence of FITC-coupled anti-CD107a (clone 1D4B,
eBioscience) and anti-CD107b (ABL-93, eBioscience) antibodies. Degranu-
lation capacity was assessed in NK cells from WT B6 and Stx11/ mice
supplemented or not with 1000 U/mL of recombinant IL-2 and compared
with nonactivated cells and the corresponding control isotype.
Preparation of macrophages and phagocytosis assay
Bone marrow–derived macrophages were prepared from WT B6 control
and Stx11/ mice by culturing precursors for 6 days in M-CSF supple-
mented medium. Cell differentiation was monitored by FACS analysis.
To determine phagocytic capacity, bone marrow–derived macrophages
were mixed for 15 minutes at 37°C with different ratios of Alexa-488–
labeled 3-m NH2-beads (Polyscience). After the pulse, the total binding
plus internalization was analyzed by FACS after resuspending the cells in
20mM citrate buffer, pH 4.0. To specifically quantify the percentage of
cells that internalized beads, the cells were resuspended in 0.2 mg/mL of
Trypan blue to quench fluorescence of noninternalized particles and
analyzed by FACS.
Statistical analysis
Data were analyzed with GraphPad Prism Version 4 software. Survival and
HLH incidence curves were analyzed using the log-rank test. All other
analyses were performed using t tests or 1-way ANOVA with posttest.
Differences were considered to be statistically significant when P 	 .05.
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Results
Age at HLH onset in FHL2, FHL4, and GS
In humans, the various molecular defects along the cytotoxic
pathway that lead to inherited forms of HLH are characterized by
similar clinical and biologic manifestations.1 In all these condi-
tions, both the type of mutation and environmental factors (includ-
ing virus exposure) can considerably modify the timing of HLH
development and the clinical presentation in susceptible patients.
Previous genotype/phenotype correlation analyses of perforin
deficiency in FHL2 have shown that age at onset is a relevant
feature of HLH severity.20,21 To establish whether deficiencies in
perforin, STX11, and RAB27A lead to similarly intense HLH, we
compared the age at HLH onset in a large cohort of patients
carrying severe biallelic mutations impairing perforin, RAB27A,
or STX11 protein expression. Two-thirds of the patients consid-
ered were previously reported (supplemental Tables 1 and 2).
All the mutations considered are null mutation, introduce a stop
codon, or affect the first base of an intron predicted to induce a
frameshift and a consecutive stop codon (supplemental Tables 1
and 2). Strikingly, the distribution of ages at HLH onset in
patients differed significantly according to the affected gene
(Figure 1A-B). Patients lacking STX11, RAB27A, and perforin,
respectively, developed HLH at a mean 
 SD age of
27.3 
 37 months, 13.4 
 19 months, and 3.4 
 5 months, respec-
tively. Intragroup variance was high for all 3 conditions, emphasiz-
ing the role of additive genetic or environmental factors in the
development of HLH in humans. In sum, these results indicate a
gradient in HLH severity, from perforin deficiency down to STX11
deficiency.
Generation of Stx11-deficient mice
To better characterize the role of STX11 in the immune
response, we generated a Stx11/ mouse model. Deletion of
exon 3 (the only coding exon in stx11) in a C57BL/6 background
led to a defect in Stx11 protein expression (Figure 2A). The
mice were fertile and grew normally. Compared with WT
C57BL/6 mice, Stx11-deficient mice presented with normal
immune cell development and differentiation. Normal counts
and proportions of NK, B, T, and antigen-presenting cells
were detected in the thymus, lymph nodes, and spleen (data
not shown). A normal ratio of CD8 to CD4 T cells was
observed in the thymus and secondary lymphoid organs (data
not shown).
Impaired degranulation of Stx11-deficient murine CTL is
complemented by full-length but not a truncated mutant of
human STX11
It has been shown that, in FHL4 patients, mutations in STX11
impair degranulation capacity of cytotoxic lymphocytes and that
this defect can be partially restored by incubation with high
concentration of recombinant IL-2.14 To establish whether or not
degranulation capacity of murine CTL was dependent on STX11
expression, CD107 cell surface expression was measured in in vitro
activated WT and Stx11-deficient murine CTL. As expected,
CD107 cell surface expression increased in WT cells after anti-
CD3 activation (Figure 2B, left top panel). In contrast, Stx11-
deficient CTL failed to degranulate on TCR engagement (Figure
2B, left bottom panel).
To confirm that the degranulation defect observed in Stx11-
deficient cells was dependent on Stx11 expression, we carried out
complementation experiments by expressing human STX11 in
murine Stx11-deficient lymphocytes. Cotransfection of human
cDNA encoding STX11 restored degranulation capacity of Stx11-
deficient cells to WT levels (Figure 2B-C). Interestingly, expres-
sion of a truncated form of STX11 (mimicking a mutation observed
in FHL4 patients) did not rescue degranulation capacity of
Stx11-deficient cells (Figure 2B-C), even though the mutant was
normally expressed (data not shown). As expected, degranulation
in WT cells was independent of cell transfection. To determine
whether or not activation of murine Stx11-deficient CTL with high
concentration of recombinant IL-2 can restore the defect in
degranulation capacity, we compared degranulation of WT and
Stx11-deficient CTL supplemented or not with 1000 U/mL of IL-2
during the culture. In contrast to human cells, IL-2 was unable to
restore degranulation capacity (Figure 2D). Similar results were
observed with murine NK cells (supplemental Figure 1). Impor-
tantly, the impaired degranulation capacity of Stx11-deficient cells
was not related to a defect in CTL activation as expression of
activation markers and T-cell proliferation was normal, as shown
by expression of CD25 and CD44 and the results of a CFSE
dilution assay (Figure 2D-E). Thus, STX11 is absolutely required
for the release of lytic granules and requires the C-terminal domain
thought to interact with intracellular membranes to function.
Figure 1. HLH onset occurs later in patients with syntaxin-11 deficiency than in patients with RAB27A- and PRF1/ deficiencies. (A) Cumulative incidence and
(B) age at onset of HLH in FHL2 (PRF1 deficiency, gray circles; n  72), GS2 (RAB27A deficiency, gray triangles; n  61), and FHL4 (STX11 deficiency, open squares; n  30)
patients carrying null biallelic mutations, as detailed in supplemental Table 1. The incidence of HLH was analyzed with a log-rank test. *P 	 .05 for FHL4 versus GS2 patients.
***P 	 .001 for FHL2 versus GS2 and FHL2 versus FHL4. The onset of HLH was analyzed with a 1-way ANOVA. **P 	 .01. ***P 	 .001.
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Relative severity of HLH in Stx11/, Rab27a/, and Prf1/mice
To establish whether there are gene-specific differences between
the 3 inherited conditions in term of HLH manifestations, a single
LCMV-injection (200 pfu) was used to induce and compare the
HLH manifestations in Prf1/, Rab27a/, and Stx11/ mouse
models. All Stx11/ mice and most of the Rab27a/ mice
survived infection in this experimental setting (Figure 3A). As
reported previously, Prf1/ mice died  2 weeks after infection
with LCMV (Figure 3A). Despite a normal survival rate, Stx11/
mice developed the clinical features of HLH, body weight loss
(Figure 3A), a drop in body temperature (Figure 3A), a hunched
posture, lethargy, and a general worsening of their condition (as
observed in Rab27a/ and Prf1/ mice). The drop in body
temperature was significantly less pronounced in Stx11/ mice
than in the other 2 murine HLH models (Figure 3A). On day 12
after infection, Stx11/, Rab27a/, and Prf1/ mice presented
the typical biologic features of HLH, including pancytopenia
(Figure 3B-C) and a lack of neutrophilia (Figure 3D). Increased
serum liver transaminase levels were also detected days 8-20 after
infection (Figure 3E), together with high serum levels of IFN- and
inflammatory cytokines, such as IL-1, TNF- and IL-6 (Figure
4A-B). It is noteworthy that the elevation in liver transaminase
levels occurred later in Stx11/ mice than in the 2 other HLH
murine models (Figure 3E). Serum levels of IFN-, known to be a
critical factor in the development of HLH, were significantly
elevated in all 3 murine models of HLH (Figure 4A). However,
IFN- levels were lower in Stx11/ mice than in the 2 other HLH
models, with Prf1/ mice always displaying the highest levels
(Figure 4A).
It has been suggested that CXCL10 expression (an IFN-
inducible gene) correlates well with the intensity of HLH activity in
patients22 and that CXCL10 could have a role in the recruitment of
lymphocytes and macrophages to inflamed tissues. To determine
whether this was the case in the HLH murine models, serum levels
of CXCL10 were assayed after LCMV infection. An increase in the
serum concentration of CXCL10 was observed in all 3 HLH
models at day 8 after infection (Figure 4C). The CXCL10 levels
correlated well with IFN- level (Figure 4D). CXCL10 transcript
expression in the spleen was also enhanced (3- to 7-fold vs WT) in
all infected mutant mice (Figure 4E). Increased expression of
CXCL10 also correlated with splenomegaly, disruption of spleen
architecture, and a marked macrophage infiltration (Figure 4F-G).
Overall, LCMV infection induced all the features of HLH in the
new Stx11/ mouse. The use of a similar experimental setting to
trigger HLH in the 3 murine models revealed a gradient of severity.
Based on several phenotypic features (including survival rates,
body temperature, serum liver enzyme, and IFN- titers), the most
intense HLH was observed in Prf1/ mice, followed by Rab27a/
mice and, lastly, Stx11/ mice.
Stx11/, Rab27a/, and Prf1/ mice have similar viral load
Defective control of LCMV infection is considered to be a key
factor in HLH pathogenesis.15 Hence, viral titers were determined
in the spleen and liver of the 3 mouse models at different time
points after LCMV infection. Immunocompetent C57BL/6 mice
cleared the LCMV in  1 week (Figure 5). In contrast, all
3 cytotoxicity-deficient HLH models failed to control the LCMV
infection (Figure 5; and data not shown). Interestingly, the viral
load did not significantly differ from one HLH model to another,
Figure 2. Stx11/ murine model and complementation of the observed degranulation defect. (A) Top panel: Schematic representation of the approach designed to
delete the exon 3 of stx11 in mice. Bottom panel: stx11 (top inset) and -actin (bottom inset) expression in WT (/) and Stx11/ CD8 T cells. (B-F) Spleen CD8 T cells from
Stx11/ and control B6 mice were activated in vitro. (B) Control B6 (top row) and Stx11/ (bottom row) CD8 T cells were cotransfected or not (control) with a plasmid coding
for CFP (pCFP) alone or together with a plasmid coding for WT STX11 (pSTX11) or a truncated form of STX11 (pSTX11-T). After transfection, degranulation was assessed on
stimulation with medium only (filled histogram) or anti-CD3 antibody (black line). (C) Graphs represent the mean 
 SEM (n  4) change in cell surface CD107 on control B6
cells (black bars) and Stx11/ cells (open bars) cotransfected or not (control) with a plasmid coding for CFP alone (pCFP) or together with a plasmid coding for WT STX11
(pSTX11) or a truncated form of STX11 (pSTX11-T). **P 	 .001. (D) Graphs represent mean
 SEM (n  3) change in cell surface expression of CD107 on control B6 (black
bars) and Stx11-deficient cells (white bars) activated in the presence (right panel) or not (left panel) of 1000 U/mL of recombinant IL-2. (E) Graph represents mean 
 SEM
(n  6) of percentage of activated CD8 T cells positive for CD25 (left panel) and CD44 (right panel). (F) Representative histograms of CFSE dilution after 3 (left panel) and
5 (right panel) days of culture of control B6 (top row) and Stx11-deficient (bottom row) CD8 T cells.
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despite the observed differences in the severity of the HLH
manifestations (see previous paragraphs). Thus, although LCMV
infection triggers HLH, the viral load does not correlate with
disease severity.
Stx11 and Rab27a deficiencies similarly impair cytotoxic
activity in vitro
To establish whether the differing HLH severity observed in the
3 HLH murine models correlated with the intensity of cytotoxicity
impairment, we assayed the degranulation capacity and/or cyto-
toxic activity of Prf1/, Stx11/, and Rab27a/ lymphocytes.
Compared with WT CTL, Stx11/ and Rab27a/ CD8 T cells
failed to degranulate on TCR activation to a similar extent (Figure
6A). The defect in degranulation capacity observed in Stx11- and
Rab27a-deficient cells was constant over time and was detected for
a broad range of TCR stimulation setting (Figure 6B-C). As
expected, normal degranulation capacity was observed in Prf1-
deficient CTL compared with control cells (Figure 6A-C). To
compare the cytotoxicity defect of the different murine models,
in vitro activated CTLs were incubated with anti-CD3–loaded
P815 target cells. Whereas WT CTLs killed target cells effi-
ciently, Stx11- and Rab27a-deficient CTLs showed reduced killing
rates to a similar extent, even at high CTL/target cell ratio (Figure
6D). Defect was more pronounced in Prf1-deficient T cells, in
accordance with the highest severity of HLH in this model (Figure
6D). Thus, although Stx11/ and Rab27a/ mice exhibit a similar
impairment in degranulation and cytotoxicity, the 2 models show
difference in HLH severity, suggesting the involvement of addi-
tional regulatory mechanism(s).
Contribution of Stx11 and Rab27a to CTL priming
Although one cannot rule out the possibility that in vitro studies do
not fully recapitulate cytotoxic function in vivo, mechanisms other
than cytotoxicity may also influence the net outcome of the
immune response during HLH. It has been shown in in vitro
experiments that Rab27a regulates phagosomal maturation and
cross-presentation in dendritic cells.23 Furthermore, in human
monocytes, STX11 was reported to be highly expressed, recruited
on phagosomes,24 and restrain phagocytosis of apoptotic bodies.25
To investigate whether Stx11 plays a role in phagocytic activity of
murine macrophages, we generated bone marrow–derived macro-
phages from control WT B6 and Stx11/ mice and phagocytosis of
3-m latex beads was assessed by FACS analysis. Stx11 deficiency
did not impair internalization of latex-bead particles, as Stx11-
deficient bone marrow–derived macrophage presented similar
phagocytic capacity as control cells (supplemental Figure 2). To
determine whether Stx11 and/or Rab27a exert a role in antigen
presentation to CD8 T cells in vivo, we transferred CFSE-labeled
P14 CD8 T cells to control, Stx11/, Rab27a/, and Prf1/ mice
that had been previously infected with LCMV and then measured
P14 CD8 T-cell proliferation. Although the 3 murine models
displayed similar viral loads (Figure 5), P14 CD8 T cells had a
higher proliferative capacity in Rab27a/ mice compared with
Stx11/ mice (Figure 7). In contrast, P14 CD8 T-cell proliferation
Figure 3. LCMV-infected Stx11/, Rab27a/, and Prf1/ mice display phenotypic manifestations of HLH of variable intensity. Stx11/ (open bars/open squares),
Rab27a/ (light gray bars/gray triangles), Prf1/ (dark gray bars/gray circles), and control B6 (black bars/black squares) mice were infected with 200 pfu of LCMV-WE.
Clinical and biochemical parameters were determined after infection. (A) Survival, body weight, and body temperature. Survival was analyzed with a log-rank test (n  12-16).
*P 	 .05. ***P 	 .001. (B) White blood cell counts. ***P 	 .001. (C) Red blood cell and platelets counts. ***P 	 .001. (D) The time course of neutrophil counts. ***P 	 .001.
(E) Serum aspartate aminotransferase (ASAT) and LDH levels in infected mice were analyzed on days 8, 12, and 20 after infection. **P 	 .01. ***P 	 .001. Data (mean
 SD)
are representative of 4 independent experiments with at least 3 mice in each group.
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was similar between Prf1/ mice and Stx11/ mice (Figure 7).
Even though C57BL/6 mice are able to clear the virus one week
after infection (Figure 5), P14 CD8 T cells were still proliferating, a
result that is consistent with the persistence of available MHC
I–peptide complexes at that time (Figure 7). These data suggest that
Rab27a and Stx11 may differently contribute to lymphocyte
activation by controlling antigen presentation, thus adding an
additional level of complexity in the mechanisms adjusting HLH
severity.
Discussion
By comparing the severity of HLH associated with perforin,
Rab27a, or syntaxin-11 deficiency, both in humans and in their
murine counterparts (including a newly generated Stx11/ mouse),
this study brings evidence that effectors of the cytotoxic activity
not only control viral infection but also regulate the immune
response.
Primary HLH is a genetically heterogeneous disease with a
relative homogeneous phenotype.1 However, considerable differ-
ences in the age of disease presentation, severity of clinical
symptoms, and duration of remission can be observed. These
differences depend on the nature of the molecular causes involved,
the type of mutations, potential additional genetic factors, and
environmental factors, including virus exposure. We have tried to
restrain some of these factors to better define the effective
contribution of 3 different causative defects in the expression of
HLH.
In humans, defects in perforin, RAB27A, or STX11 were
correlated with the age of HLH presentation. Age of HLH onset
was previously shown to be a reliable marker of HLH severity in
FHL2 patients.20,21 To limit the effect of mutation variations, only
the patients with biallelic mutations predicting complete loss of
protein expression were considered among those previously re-
ported or genetically characterized in the context of this study. Still,
Figure 4. Different levels of inflammatory cytokines are detected in LCMV-infected Stx11/, Rab27a/, and Prf1/ mice. Stx11/ (open bars/open squares),
Rab27a/ (light gray bars/gray triangles), Prf1/ (dark gray bars/gray circles), and control B6 (black bars/black squares) mice were infected with 200 pfu of LCMV-WE.
(A) The time course of serum IFN- production. ***P 	 .001 for control B6 versus Stx11/ and Rab27a/ versus Prf1/ at day 8. ***P 	 .001 for Stx11/ versus Rab27a/
and Stx11/ versus Prf1/ at day 8. ***P 	 .001 for Rab27a/ versus Prf1/ at day 8. (B) Serum IL-1 (left panel) and TNF- levels (right panel) on day 12 after infection.
(C) The time course of serum CXCL10 production. (D) Correlation between serum levels of IFN- and CXCL10 on day 8 after infection. (E) CXCL10 mRNA in spleen of infected
mice. **P 	 .001. (F) Hematoxylin and eosin staining of representative spleen sections of control B6 (left panel) and STX11/ (right panel) mice 3 weeks after LCMV infection.
(G) FACS analysis of spleen cells from control B6 (left panel) and Stx11/ (right panel) mice 3 weeks after LCMV infection, gated on I-Ab cells. Data (mean 
 SEM) are
representative of 3 independent experiments with at least 3 mice in each group.
Figure 5. Defective control of LCMV infection in Stx11/, Rab27a/, and
Prf1/ mice. Stx11/ (open squares), Rab27a/ (gray triangles), Prf1/ (gray
circles), and control B6 (black squares) mice were infected with 200 pfu of LCMV-
WE. After 8 or 12 days after infection, LCMV titers in the spleen were determined.
Data (mean 
 SEM) are representative of 3 independent experiments with at least
3 mice in each group. *P 	 .05. ***P 	 .001.
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a gradient in HLH severity was observed in humans from perforin
deficiency down to STX11 deficiency.
The impact of environmental factors and potential additive
genetic factors on HLH severity is difficult to appreciate in
humans. Thus, animal models of HLH were considered for
analyzing the manifestations of HLH in details while controlling
these 2 factors. Perforin and Rab27a murine models have been
previously engineered or occurred as natural mutant, respec-
tively.15,16 Here, we generated a syntaxin-11 murine model and, as a
first step, evaluated whether or not it recapitulates FHL4 features
observed in other HLH murine models.
Stx11/ mice exhibited a defective degranulation and cytotoxic
activity of lymphocytes in vitro, confirming the critical role of this
SNARE protein in cytotoxic granule exocytosis. Degranulation
defect was complemented by the expression of a full-length human
syntaxin-11 protein but not by a protein lacking the last 32 amino
acids. The mutant form of STX11 retains the SNARE and the Habc
domains, 2 domains thought to interact when SNARE proteins
adopt a closed conformation.26 In contrast, the STX11 mutant lacks
the C-terminal domain that contains a putative palmitoylation site
thought to mediate membrane association.13 Membrane localiza-
tion and switch of the syntaxin-11 protein from a closed to an open
conformation are required for SNARE complex formation. This is
probably why the truncated form of syntaxin11 is unable to restore
lytic granule exocytosis. The Stx11/ mouse should thus be a
powerful tool for precisely identifying STX11 regulated steps and
the molecular mechanisms involved in CTLs and, potentially, in
other immune cells.
As previously shown for perforin- and Rab27a-deficient mice,
LCMV infection induced the clinical, biologic, and histologic
features of HLH in the new Stx11/ mouse. Although the
Stx11-deficient mice survived, they develop characteristic features
of HLH, including pancytopenia, elevated serum level of IFN-,
CXCL10 and inflammatory cytokines, increased levels of liver
transaminase, and spleen macrophage infiltration. Stx11/ mouse
therefore constitutes a suitable model of FHL4.
A similar experimental setting was then used to compare the
manifestations of HLH in the 3 murine models. Remarkably, the
intensity of HLH in mice fully paralleled the severity of the disease
observed in human HLH patients. Prf1/ mice expressed the most
severe manifestations followed by Rab27a/ mice, whereas HLH
features in Stx11/ mice were the less intense. Thus, even in
controlled environment and genetic background, the same differ-
ences in HLH severity, previously observed in humans, were
demonstrated in the murine models. This further validates the used
of HLH murine models as suitable tools for studying the mecha-
nism of HLH development in humans. Furthermore, this indicates
that the functional consequences associated with each molecular
defect significantly differ.
Cytotoxicity defect allowing virus persistence results in T-cell
activation and the development of HLH. The 3 cytotoxic-deficient
mice failed to clear LCMV infection. However, no difference in the
virus load could be detected between them, a finding that could
have impacted HLH severity. This suggests that, in addition to a
role in virus clearance, the cytotoxic activity of lymphocytes may
also contribute to the regulation of immune reactions. Such
additional mechanisms may influence the outcome of the immune
response by influencing the balance between control of the immune
response and a lethal immunopathology. Indeed, the cytotoxic
activity may be involved in a “fratricide” mechanism, enabling the
Figure 6. Intensity of CTL degranulation capacity and
cytotoxicity in Stx11/, Rab27a/, and Prf1/ mice.
Spleen CD8 T cells from Stx11/, Rab27a/, Prf1/,
and control B6 mice were activated in vitro. (A) A
representative FACS analysis for degranulation of CD8
T cells from control B6 (left panel), Stx11/ (left middle
panel), Rab27a/ (right middle panel), and Prf1/ mice
(right panel) on stimulation with medium (bottom row) or
anti-CD3 antibody (top row). (B-C) Graphs show the
mean 
 SEM (n  5) CD107 variation on control B6
(black squares), Stx11/ (open squares), Rab27a/
(gray triangles), and Prf1/ (gray circles) CD8 T cells
after anti-CD3 stimulation over time (B) or with different
concentrations of anti-CD3 antibody (C). *P 	 .05.
**P 	 .01. ***P 	 .001. (D) Cytotoxicity was determined
in activated CD8 T cells after incubation with target
anti-CD3–loaded P815 cells for 3 hours. Data (mean

 SEM) are representative of 3 independent experi-
ments performed in triplicate. *P 	 .05. **P 	 .01.
***P 	 .001.
Figure 7. Increased cross-presentation in Rab27a/
mice in vivo. CFSE-labeled P14 CD8 T cells were
transferred to LCMV-infected control B6, Stx11/,
Rab27a/, and Prf1/mice. The figure shows represen-
tative histograms of CFSE staining in P14 cells 3 days
after transfer (right panel) and the proportion of P14 cells
having divided between 0 and 5 times (black bars) or
more than 5 times (white bars). Graphs represent the
mean 
 SD value from 2 independent experiments with
3 mice in each group. *P 	 .05. **P 	 .01. ***P 	 .001.
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immune response to be down-regulated. This hypothesis is further
supported by the in vitro observation that, once CTLs have
captured membrane fragments from previously killed targets, they
themselves can become targets for sister CTLs.27 Importantly,
recent research also suggests that the cytotoxic activity of NK cells
plays a direct role in the down-regulation of T cell–dependent viral
persistence. A lack of NK cells was indeed shown to increase the
proportion of antigen-specific CTLs after LCMV infection28-30 and
hence could facilitate lethal, T cell–mediated diseases. The cyto-
toxic activity of lymphocytes may thus regulate the outcome of
immune responses through a variety of potentially additive mecha-
nisms, allowing a small difference in lymphocyte cytotoxicity in
vitro to carry a significant impact in vivo on the regulation of the
immune response.
Cytotoxic activity was found severely impaired in all 3 murine
models. However, the defect in lymphocytes lacking perforin
expression was more pronounced. Through additive cytotoxic-
dependent regulatory mechanisms, this subtle in vitro difference
may account for the most severe disease expression and lethality
observed in vivo in Prf1/ mice. In contrast, the similar cytotoxic
impairment observed in Stx11/ and Rab27a/ mice does not
correlate with differences in the intensity of HLH manifestations.
This suggests that additional regulatory mechanism(s), other than
cytotoxicity, may also play a role. Rab27a and syntaxin-11 are
broadly expressed, in particular in myeloid cells, and may thus
potentially regulate phagocytosis and cross-presentation of antigen.
A direct role of these proteins in nonlymphoid cells would add
another level of complexity in the mechanisms regulating HLH
manifestations. Change in phagosomal function and antigen cross-
presentation of Rab27a-deficient dendritic cells has been previ-
ously reported in vitro.23 Interestingly, we observed an increased
antigen-specific CD8 T-cell proliferation in vivo when antigen-
presenting cells are Rab27a-deficient, supporting a role of Rab27a
in antigen presentation. Our work did not allow so far to detect a
significant role of syntaxin-11 in antigen presentation, either
in vitro or in vivo. Whether or not differences in HLH severity
between Stx11/ and Rab27a/ models could be related to
differential contributions of these proteins to CTL activation,
indirectly via the control of antigen presentation in vivo, will
require further studies.
Deciphering the factors that fine-tune the severity of HLH
allows to better understand the mechanisms of HLH pathogenesis,
in particular, and those regulating the immune response, in general.
This should be particularly relevant to approach the pathophysiol-
ogy of some types of secondary HLH, which frequently do not
express the full picture of HLH. The mouse experiments provide
evidence that virus control is a key but not an exclusive variable of
LCMV-induced HLH, supporting a direct immune regulatory role
of the cytotoxic function of lymphocytes. The HLH murine models
are shown here to be reliable counterparts and will be powerful
tools to further depict this regulatory mechanism as well as the
precise function of these effectors independently of the cytotoxic
pathway.
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